This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Intermittent Claudication industry.
What is the anticipated market size of the intermittent claudication industry over the next few years?
The intermittent claudication market size has grown strongly in recent years. It will grow from $12.81 billion in 2024 to $13.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rise in peripheral artery disease, increase in awareness regarding vascular diseases, growth in geriatric population, increase diagnosis rates, and rise in healthcare expenditure.
The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing prevalence of diabetes, rising prevalence of obesity, increasing prevalence of cardiovascular diseases, rising alcohol and tobacco consumption, and increasing healthcare spending. Major trends in the forecast period include advancements in pad diagnostics, integration of wearable devices, personalized medicine integration, shift towards drug-eluting stents, and advancements in stem cell therapy.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp
What emerging drivers are expected to shape the future of the intermittent claudication market?
The increasing cases of peripheral artery disease (PAD) are expected to fuel the growth of the intermittent claudication market going forward. Peripheral artery disease refers to a circulatory condition where narrowed arteries reduce blood flow to limbs, causing pain, numbness, and complications. Increasing cases of peripheral artery disease are attributed to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. Peripheral artery disease (PAD) causes intermittent claudication by reducing blood flow to leg muscles during exercise, leading to pain and cramping due to oxygen deprivation. For instance, in June 2023, according to the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) affects 7-12 million in the U.S. and 200 million globally. Therefore, the increasing cases of peripheral artery disease (PAD) are driving the growth of the intermittent claudication market.
What emerging segments are shaping the future landscape of the intermittent claudication industry?
The intermittent claudication market covered in this report is segmented –
1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report
What technological trends are expected to redefine the intermittent claudication market?
Major companies operating in the intermittent claudication market are focusing on advanced medication therapies, such as RIPK1 inhibitors, to enhance treatment outcomes for patients suffering from peripheral artery disease (PAD) with intermittent claudication, aiming to improve blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors refer to targeted drugs that block RIPK1 kinase activity, reducing inflammation and cell death. For instance, in August 2022, GenFleet, a China-based biotechnology company, received US Food and Drug Administration (FDA) approval for a Phase II clinical trial of GFH312, an innovative therapy for peripheral artery disease (PAD) with intermittent claudication (IC). This randomized, double-blinded, placebo-controlled study will be conducted at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promise in preclinical studies by curbing the inflammatory response in animal models.
How are key players in the intermittent claudication market strengthening their market position?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.
Which geographic areas are contributing significantly to the growth of the intermittent claudication sector?
North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Intermittent Claudication Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021
Need Customized Data On Intermittent Claudication Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
